|
|
Post by figglebird on Sept 4, 2018 18:04:08 GMT -5
What molecules/meds would any care to guess might be in play beyond epi, thc, flu?
|
|
|
|
Post by mnholdem on Sept 4, 2018 18:37:48 GMT -5
Non-addictive pain management. Expensive development with potentially huge returns.
|
|
|
|
Post by peppy on Sept 4, 2018 18:57:24 GMT -5
COPD. from MN "United Therapeutics’ CEO doesn’t seem to be the kind of person who would stab MannKind in the back. As you mentioned, her company has a COPD candidate in clinical testing. It seems that she could take full advantage of “Your Drug. Our Delivery.” - see MannKind Corporate website Partnering page." I looked at the UTHR products and pipeline. I couldn't find a name on the COPD candidate. All UTHR products that tx PAH would be candidates. I like COPD. Give life back to these people. Here is what I think I know. Meconium aspiration a bit like COPD. I believe surfactant helps meconium aspiration patients, it may do the same for COPD. However I can be wrong. Used in neonatal units it is used for respiratory distress, and man does it work. MN, do you see a name on UTHR COPD candidate. Life for the very difficult. www.accessdata.fda.gov/drugsatfda_docs/label/2012/021746s000lbl.pdf11 DESCRIPTION SURFAXIN (lucinactant) Intratracheal Suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a synthetic formulation consisting of phospholipids, a fatty acid, and sinapultide (KL4 peptide), a 21-amino acid hydrophobic synthetic peptide. The chemical names, structures, and empirical formulas of the 4 active components of SURFAXIN are: Sinapultide (KL4 acetate) Chemical Name: L-Lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L Structure: Empirical Formula: C126H238N26O22 Molecular Weight: 2469.46 leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysine, acetate 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Endogenous pulmonary surfactant lowers surface tension at the air-liquid interface of the alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting transpulmonary pressures. A deficiency of pulmonary surfactant in premature infants results in RDS. SURFAXIN compensates for the deficiency of surfactant and restores surface activity to the lungs of these infants. |
|
|
|
Post by lennymnkd on Sept 4, 2018 18:59:39 GMT -5
How about a molecule called embarrassment of riches ! Had to throw that one in there for you MATT P.😀👍
|
|
|
|
Post by mango on Sept 4, 2018 20:33:45 GMT -5
Oxytocin for postpartum hemorrhage (I believe this will get developed sooner rather than later).
Dry powder formulation for chronic regional pain syndrome (Pure speculation by me. However, there is zero FDA approved CRPS specific medications so this is a seriously huge, urgent unmet medical need).
I second Peppy. TechnoSurf.
You had it right, meconium babies require surfactant. The formulation and method for administration needs to be updated and mproved. I envision a dry powder formulation delivered in a simple fashion via an easy to use, next generation disposable bronchoscope that MannKind would need to invent, called the Surfactoscope. This device would dual function as a bronchoscope and an dry-powder surfactant dispensing apparatus, this way images can be taken of the airways before, during and after and would be easy to use by any trained medical person. The Surfactoscope would contain pre-measured, precise dosages that would be delivered with the push of a button. This device could also be used in veterinary hospitals and clinics.
|
|
|
|
Post by peppy on Sept 4, 2018 20:36:43 GMT -5
Oxytocin for postpartum hemorrhage (I believe this will get developed sooner rather than later). Dry powder formulation for chronic regional pain syndrome (Pure speculation by me. However, there is zero FDA approved CRPS specific medications so this is a seriously huge, urgent unmet medical need). I second Peppy. TechnoSurf. You had it right, meconium babies require surfactant. The formulation and method for administration needs to be updated and mproved. I envision a dry powder formulation delivered in a simple fashion via an easy to use, next generation disposable bronchoscope that MannKind would need to invent, called the Surfactoscope. This device would dual function as a bronchoscope and an dry-powder surfactant dispensing apparatus, this way images can be taken of the airways before, during and after and would be easy to use by any trained medical person. This device could also be used in veterinary hospitals and clinics. oh man technoSurf. love it. COPD baby. Man those people suffer. |
|
|
|
Post by mnholdem on Sept 4, 2018 22:08:01 GMT -5
I totally agree with you, peppy, that UTC will be developing a COPD treatment using Technosphere.  |
|
|
|
Post by mango on Sept 4, 2018 22:19:10 GMT -5
Oxytocin for postpartum hemorrhage (I believe this will get developed sooner rather than later). Dry powder formulation for chronic regional pain syndrome (Pure speculation by me. However, there is zero FDA approved CRPS specific medications so this is a seriously huge, urgent unmet medical need). I second Peppy. TechnoSurf. You had it right, meconium babies require surfactant. The formulation and method for administration needs to be updated and mproved. I envision a dry powder formulation delivered in a simple fashion via an easy to use, next generation disposable bronchoscope that MannKind would need to invent, called the Surfactoscope. This device would dual function as a bronchoscope and an dry-powder surfactant dispensing apparatus, this way images can be taken of the airways before, during and after and would be easy to use by any trained medical person. This device could also be used in veterinary hospitals and clinics. oh man technoSurf. love it. COPD baby. Man those people suffer. Peppy, surfactant for COPD seems like it would help, but COPD is an obstructive disease. RDS there is insufficient surfactant production because of the immature lung development (AT2C). I want to think about how we can develop a COPD formulation that restores lung function by restoring essential function and development in gas exchange anatomy like alveolar-capillary membranes, ducts and sacs and also restore connective tissue, repair dilated and narrowed airways, areas of atelectasis etc..all without using stem cells or man-made organs. Having command of the immune cells would be nice, maybe if the formulation could interact with the endocannabinoid system, the CB2 receptor modulates immune cells and lung tissue macrophages express both the CB1 and CB2 receptors, alveolar cells express cannabinoid receptors too... In this idea, the cannabinoid receptors modulate lung tissue macrophages in vascular repair and remodeling, connective tissue, smooth muscle, in suppressing inflammation, killing cancer cells etc...inducing apoptosis in cancer cells via cannabinoid receptors and/or Anandamide With alveolar macrophages, which also express cannabinoid receptors, we could modulate the remodeling and repair of the mucociliary transport system and eradicate the pulmonary alveolus from threats like harmful bacteria, cancer cells, unwanted inflammatory responses, etc… Peppy, in this way we can directly increase endogenous surfactant production via alveolar type 2 cells using compounds that interact with mitochondria cannabinoid receptors in alveolar type 2 cells promoting ATP synthesis and cellular respiration thus stimulating surfactant production in a premie while also restoring balance and continued development of essential lung anatomy and physiology. |
|
|
|
Post by peppy on Sept 4, 2018 22:52:06 GMT -5
Mango, Meconium aspiration an obstructive disease. black tarry stool at the neck of the alveoli.
it's the decreased surface tension that will/might help if?
Shot in the dark I know.
I hear COPD and I see the constriction.
|
|
|
|
Post by mango on Sept 4, 2018 23:03:13 GMT -5
Peppy, after thinking more, I think I need to revisit your surfactant theory, but would restoring alveolar cell function prevent the person's lungs from functioning in a COPD fashion? The air trapping, airway dilation and narrowing, inflammation, connective tissue damage, infections etc, but I think you are on to something here. We would need to make sure extracellular ATP is regulated properly, apparently it needs to be just right there's a sweet spot, what do you reckon it is?. Surfactant secretion is a similar fashion like insulin secretion, it is through exocytosis. Do you reckon surfactant release is similar to insulin release, where the alveolar cells function in synchrony and secrete in phases? Maybe even form alveolar memory from ATP or some other information containing source? Surfactant secretion is stimulated by a bunch of stuff, but extracellular ATP seems to be the major player. Seems like an endocannabinoid buffer would be useful.
|
|
|
|
Post by mango on Sept 4, 2018 23:04:46 GMT -5
Mango, Meconium aspiration an obstructive disease. black tarry stool at the neck of the alveoli. it's the decreased surface tension that will/might help if? Shot in the dark I know. I hear COPD and I see the constriction. Peppy, last time I saw meconium aspiration baby went blue and had to be brought back to life. We never told the mother, the baby ended up just fine. Baby received surfactant later. |
|
|
|
Post by peppy on Sept 4, 2018 23:15:44 GMT -5
mango Probably easier to do, gone generic now? Technosphere would re up the price point? Mango, UTHR has a "fil" product. (tadalafil) oh haha. www.unither.com/products.htmlcould. pi.lilly.com/us/adcirca-pi.pdf the scientific name, I see the humor in the "Tada"
|
|
|
|
Post by mango on Sept 4, 2018 23:19:14 GMT -5
Mango, Meconium aspiration an obstructive disease. black tarry stool at the neck of the alveoli. it's the decreased surface tension that will/might help if? Shot in the dark I know. I hear COPD and I see the constriction. Peppy, I am thinking that if surfactant were chronically administered then lung compliance would become a mess and worsen the situation. Maybe it would make sense in the earliest stages or not given judicially? Lung mechanics are already totally botched with airways collapsed, narrowed, dilated, inflamed, etc..surfactant under these situations could cause dangerously high compliance since patient already has emphysema (high lung compliance). Worse case it would worsen gas exchange and air trapping. |
|
|
|
Post by peppy on Sept 4, 2018 23:21:08 GMT -5
mango Probably easier to do, gone generic now? Technosphere would re up the price point? Mango, UTHR has a "fil" product. (tadalafil) oh haha. www.unither.com/products.htmlcould. pi.lilly.com/us/adcirca-pi.pdf the scientific name, I see the humor in the "Tada" heh,imagine the animal studies. |
|
|
|
Post by peppy on Sept 4, 2018 23:22:13 GMT -5
Mango, Meconium aspiration an obstructive disease. black tarry stool at the neck of the alveoli. it's the decreased surface tension that will/might help if? Shot in the dark I know. I hear COPD and I see the constriction. Peppy, I am thinking that if surfactant were chronically administered then lung compliance would become a mess and worsen the situation. Maybe it would make sense in the earliest stages or not given judicially? Lung mechanics are already bathed with airways collapsed, narrowed, dilated, inflamed, etc..surfactant under these situations could cause dangerously high compliance since patient already has emphysema. in babies with RDS given through the endotracheal tube. |
|
